-

iHealthScreen Inc. Provides A Telemedicine platform callMyDoctor™: An Android and iOS APP

iHealthScreen’s callMyDoctor is HIPAA Compliant, Enables Automated Scheduling, and Provides Recording to Facilitate Insurance Reimbursement

NEW YORK--(BUSINESS WIRE)--callMyDoctor provides an Android and iOS app platform with telemedicine capabilities that enables patient scheduling, prescription, and the call recording facilities typically required for insurance reimbursement.

The apps can be downloaded and installed by users from standard app stores. The product is easy to use: the patient schedules the appointment, the doctor accepts the invite, the doctor can initiate the telemedicine call and record and send prescriptions to the patient. Other intelligent features include automatic medication-name completion simply from typing the initials of the medicine: this capability was created through the indexing of thousands of prescription and OTC compounds listed in official medicine databases.

The callMyDoctor app can be used by primary or tertiary care physicians with no requirement for a long-term contract.

iHealthScreen company is open to partnerships for distribution and/or co-development of its products in various geographies. For more information: https://www.iHealthScreen.org

Contacts

Alauddin Bhuiyan, Ph.D.
CEO, iHealthScreen Inc.
E: bhuiyan@ihealthscreen.org
T: +1 718 926 9000

Industry:

iHealthScreen

Release Versions
English
Hashtags
#AI
#AISoftware
#AMD
#CE
#ColorFundus
#DR
#DiabeticRetinopathy
#EarlyDiagnosis
#EyeDisease
#FDA
#GlaucomaSuspect
#MacularDegeneration
#Screening
#glaucoma
#iHealthScreen
#iPredict

Contacts

Alauddin Bhuiyan, Ph.D.
CEO, iHealthScreen Inc.
E: bhuiyan@ihealthscreen.org
T: +1 718 926 9000

Social Media Profiles
iHealthScreen Inc.
iHealthScreen Inc.
More News From iHealthScreen

iHealthScreen Receives U.S. FDA 510(k) Clearance (K253704) for iPredict-DR, an AI-Powered Software for Automated Diabetic Retinopathy Screening

RICHMOND HILL, N.Y.--(BUSINESS WIRE)--iHealthScreen, Inc., a healthcare AI company developing Software as a Medical Device (SaMD) for retinal and cardiovascular disease screening and preventive healthcare, today announced FDA 510(k) clearance (K253704) for iPredict-DR™, its AI-powered software that automatically detects more than mild diabetic retinopathy (mtmDR) in adults with diabetes not previously diagnosed with the condition. Diabetic retinopathy is a leading cause of preventable blindness...

iHealthScreen Developed and Validated Risk Prediction Models for Cardiovascular Diseases Using Individual’s Retinal Color Images and Health Data

NEW YORK--(BUSINESS WIRE)--iPredict™ Stroke and heart attack prediction models provide AI-based automated prediction scores for incident stroke and heart attack (i.e., myocardial infarction (MI)) which identifies the individuals who are at risk of having stroke and MI within 5 years. These results were peer-reviewed and accepted by the scientific review team and will be presented at the ESC Congress which will be held between 30th August and 2nd September 2024. The iPredict stroke and MI predic...

iHealthScreen Inc. is Awarded a US Patent on Glaucoma Detection, Which Is Based on AI and Color Fundus Imaging

NEW YORK--(BUSINESS WIRE)--iPredictTM glaucoma detection model provides a fully automated detection report for glaucoma which can be implemented in the primary care settings for screening and detection of early-stage glaucoma. The full US patent was awarded by USPTO on March 26, 2024. Earlier the results were published in a scientific journal and the results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024. The early screening and detection of glaucoma c...
Back to Newsroom